BriaCell Therapeutics (TSE:BCT) has disclosed a new risk, in the Accounting & Financial Operations category.
BriaCell Therapeutics faces significant financial risks if their revenue, expense, or capital and liquidity projections prove inaccurate or if the cash from operations falls short of liquidity requirements. The company acknowledges the need for potential additional financing to maintain flexibility for future acquisitions or investments. However, securing such financing could be challenging due to volatile capital market conditions, particularly as a nascent player in the pharmaceutical industry, which may affect its ability to execute business plans or respond to competitive pressures. Furthermore, any equity financing could dilute existing shareholders, with potential preferences favoring new investors, thereby impacting the company’s financial stability and operational outcomes adversely.
The average TSE:BCT stock price target is C$20.83, implying 1,665.25% upside potential.
To learn more about BriaCell Therapeutics’ risk factors, click here.
